Leah Lawrence | Authors

Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer

September 30, 2019

Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.